Literature DB >> 8944665

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.

H Nakabayashi1, M Nishizawa, A Nakagawa, R Takeda, A Niijima.   

Abstract

Among proglucagon-derived peptides, the truncated form of glucagon-like peptide-1, GLP-1(7-36)amide (tGLP-1), is known as the most likely physiological humoral incretin. To examine whether there exists any relationship between tGLP-1 levels in the portal vein and activities of the hepatic and pancreatic vagal system, changes of the impulse discharge rate in the hepatic afferent vagus and the pancreatic efferent vagus upon intraportal tGLP-1 injection were measured in situ in rats anesthetized with urethan and chloralose. First, a 1-min bolus tGLP-1 injection at a periphysiological dose of 0.2 pmol or a pharmacological dose of 4.0 pmol, but not the vehicle injection, significantly facilitated the hepatic vagal afferents for > 90 min, showing weaker facilitation at the 0.05 pmol dose. Notably, the injection of noninsulinotropic full-length GLP-1 failed to facilitate the afferents at the 4.0 or 40.0 pmol dose. Second, the intraportal tGLP-1 injections at the 0.05 and 0.2 pmol dose facilitated marginally and significantly the pancreatic vagal efferents in normal rats, respectively, but had no effect on the hepatic vagotomized rats, even at the 40.0 pmol dose. The present results indicate that an intraportal appearance of tGLP-1 is specifically recognized by the hepatic vagal nerve, and this recognition further augments the pancreatic vagal efferent activity in a reflex way, suggesting another nature of tGLP-1 as neuroincretin in the enteroinsular axis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944665     DOI: 10.1152/ajpendo.1996.271.5.E808

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  56 in total

1.  Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms.

Authors:  Jingchuan Zhang; Robert C Ritter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-26       Impact factor: 3.619

Review 2.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

Review 3.  Brain GLP-1 and insulin sensitivity.

Authors:  Darleen Sandoval; Stephanie R Sisley
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

4.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

Review 5.  GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.

Authors:  Valeria Guglielmi; Paolo Sbraccia
Journal:  Eat Weight Disord       Date:  2016-12-31       Impact factor: 4.652

6.  Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit?

Authors:  Hans-Rudolf Berthoud
Journal:  Endocrinology       Date:  2008-10       Impact factor: 4.736

Review 7.  Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions.

Authors:  Kirsteen N Browning; R Alberto Travagli
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.

Authors:  Matthew J Potthoff; Austin Potts; Tianteng He; João A G Duarte; Ronald Taussig; David J Mangelsdorf; Steven A Kliewer; Shawn C Burgess
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-20       Impact factor: 4.052

10.  Direct effect of GLP-1 infusion on endogenous glucose production in humans.

Authors:  M Seghieri; E Rebelos; A Gastaldelli; B D Astiarraga; A Casolaro; E Barsotti; A Pocai; M Nauck; E Muscelli; E Ferrannini
Journal:  Diabetologia       Date:  2012-10-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.